Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

Enhertu (fam-trastuzumab deruxtecan-nxki*) is a prescription drug used to treat certain kinds of cancer, including breast cancer. Enhertu is given by intravenous infusion (an injection into a vein ...

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

How Do I Use Enhertu for Breast Cancer? Doses of Enhertu are given as an IV through a blood vessel in your arm over a period of time. Your dose will be given by a health care provider every 3 ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...